Risk of early non-cancer deaths in adults diagnosed with metastatic genitourinary (mGU) cancers: A retrospective cohort study.

Authors

Ahsan Ayaz

Ahsan Ayaz

Montefiore St. Luke's Cornwall Hospital, Newburgh, NY

Ahsan Ayaz , Syed Arsalan Ahmed Naqvi , Zaryab Bin Riaz , Arifa Bibi , Kaneez Zahra Rubab Khakwani , Ewan Kemar Cobran , Parminder Singh , Alan Haruo Bryce , Irbaz Bin Riaz , Sajid Ahmad Mir

Organizations

Montefiore St. Luke's Cornwall Hospital, Newburgh, NY, Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, Rashid Latif Medical College, Lahore, Pakistan, University of Arizona, Tucson, AZ, Mayo Clinic College of Medicine and Science, Scottsdale, AZ, Mayo Clinic, Phoenix, AZ, Mayo Clinic Arizona, Scottsdale, AZ, Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, Montefiore St. Luke's Cornwall Program, Newburgh, NY

Research Funding

No funding sources reported

Background: We aim to investigate non-cancer cause of death in adults within 2 years after initial diagnosis of mGU cancers including bladder cancer (BC), kidney cancer (KC), and prostate cancer (PC). Methods: Surveillance, Epidemiology, and End Results (SEER) database (2004-2020) was searched to obtain data on death caused by cardiovascular diseases (CVD), kidney diseases (KD), respiratory diseases (RD), liver diseases (LD), diabetes mellitus (DM), and sepsis in adults (>20y of age) diagnosed with mGU cancers. Standardized mortality ratios (SMRs) with 95% confidence interval (CI) were calculated within 2y of initial diagnosis. SMR was defined as the observed deaths from each category divided by the expected number of deaths in the age-matched US population for the same period. SMR >1 indicated increased while <1 indicated decreased mortality. Stratification factors included age (<50y, 50-70y, >70y), race (White, Black, Asian/Pacific Islander), ethnicity (Hispanic, non-Hispanic), chemotherapy, and radiotherapy. Results: This study including 77,246 mGU cancer patients showed that the greatest risk of early death was observed to be caused by sepsis (SMR: 4.21, 95% CI: 3.64-4.84) followed by CVD (1.70, 1.62-1.80), KD (1.58, 1.31-1.90), LD (1.58, 1.16-2.09), DM (1.56, 1.32-1.82), and RD (1.38, 1.22-1.56). Patients aged <50y observed the highest risk of mortality caused by sepsis (61.76, 30.83-110.5) followed by KD (28.06, 9.11-65.48) and CVD (5.63, 3.60- 8.84). However, patients aged 50-70y were more likely to die by RD (2.47, 1.94-3.09) and LD (2.01, 1.38-2.82). The results were consistent for Black patients; sepsis (6.59, 5.04-8.46) followed by RD (2.01, 1.41-2.78) and KD (1.64, 1.04-2.46). Asian/Pacific Islanders were more likely to die from CVD (2.52, 2.13- 3.00) and DM (2.21, 1.21-3.71). Hispanics were more likely to die from LD (3.11, 1.66-5.32) and non-Hispanics from sepsis (4.28, 3.68-4.96). This risk of death due to sepsis was increased with chemotherapy (7.06, 5.22-9.33) and radiotherapy (4.92, 3.58-6.61). Detailed results are available in Table. Conclusions: Sepsis remained the leading cause of early non-cancer-deaths in mGU cancers consistently across all subgroups. Younger adults were more likely to die from CVD and KD, Black patients from RD, and Hispanics from LD.

Cause of DeathAll GU CancersBCKCPC
SMR (95 % CI)
Sepsis4.21 (3.64-4.84)14.75 (10.22-20.61)8.69 (6.53-11.34)2.84 (2.33-3.43)
Cardiovascular diseases1.70 (1.62-1.80)3.95 (3.56-4.40)]2.91 (2.70-3.13)1.43 (1.34-1.53)
Kidney diseases1.58 (1.31-1.90)3.35 (1.67-6.0)4.93 (3.54-6.69)1.02 (0.78-1.31)
Liver diseases1.58 (1.16-2.09)1.74 (0.36-5.08)1.61 (0.77-2.97)1.55 (1.08-2.16)
Diabetes mellitus1.56 (1.32-1.82)2.42 (1.25-4.22)3.00 (2.17-4.06)1.26 (1.03-1.53)
Respiratory diseases1.38 (1.22-1.56)3.65 (2.57-5.03)2.36 (1.81-3.02)1.07 (0.92-1.25)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Other

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 229)

DOI

10.1200/JCO.2024.42.4_suppl.229

Abstract #

229

Poster Bd #

K17

Abstract Disclosures

Similar Abstracts

First Author: Ahsan Ayaz

First Author: Sarah Elizabeth Eichinger